Table 1. Patient demographic characteristics.

Variable	Result
Median age (IQR), years	61 (53, 67)
Sex, male/female	139 (58.9)/97 (41.1)
Median time since liver transplant (IQR), months	50.9 (19.6, 119.8)
Current immunosuppression medication
Primary
Tacrolimus	190 (80.5)
Cyclosporine	25 (10.6)
Sirolimus	23 (9.7)
Adjunct
Mycophenolate	78 (33.1)
Prednisone	39 (16.5)
Ethnicity
Non-Hispanic white	99 (41.9)
Hispanic white	89 (38.7)
African American	13 (5.5)
Asian	26 (11.0)
Native American	3 (1.2)
Other	9 (3.8)
Indication for liver transplantation
Hepatitis B	20 (8.5)
Hepatitis C	125 (53)
Alcoholic cirrhosis	35 (14.8)
Autoimmune hepatitis	14 (5.9)
Non-alcoholic fatty liver disease	31 (13.1)
Other†	37 (15.7)
Pre-transplant hepatocellular cancer	34 (14.4)
History of smoking	206 (87.3)
Pre-transplant
Diabetes mellitus	49 (20.8)
Hypertension	90 (38.1)
High cholesterol	40 (17.0)
High triglycerides	49 (20.8)
Post-transplant
Diabetes mellitus	64 (27.1)
Hypertension	129 (54.7)
High cholesterol	59 (25)
High triglycerides	24 (10.2)
Body mass index, median (IQR)
Before transplant	28 (24.4, 31.2)
After transplant, first clinic visit	26 (23.2, 29.9)
Current	26.8 (24.2, 30.4)
Education
Less than high school	9 (3.8)
High school	123 (52.1)
College	46 (19.5)
Graduate	35 (14.8)
Other	23 (9.7)
Estimated annual income
<$50,000	114 (48.3)
$50,000–100,000	79 (33.5)
>$100,000	43 (18.2)
Employment status
Employed	82 (34.7)
Retired	93 (39.4)
Other	61 (25.8)
<35 hours/week	18 (8.5)
>35 hours/week	50 (23.6)

Data are presented as n (%), unless otherwise indicated. IQR, interquartile range.

^†Other reasons for transplant: cryptogenic cirrhosis, Wilson’s disease, acute liver failure, primary biliary cirrhosis, hemochromatosis, benign tumor, polycystic liver disease, alpha-1-antitrypsin disease.